CLINICAL TRIALS PROFILE FOR RITALIN

All Clinical Trials for RITALIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018863 ↗	Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)	Completed	National Institute of Mental Health (NIMH)	Phase 3	2001-04-01	This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00018863 ↗	Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)	Completed	New York State Psychiatric Institute	Phase 3	2001-04-01	This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00025779 ↗	Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders	Completed	National Institute of Mental Health (NIMH)	N/A	2001-10-01	This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	Oregon Health and Science University	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	US Department of Veterans Affairs	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗	Methylphenidate for Depressed Cancer Patients Receiving Palliative Care	Completed	VA Office of Research and Development	N/A	2005-02-01	The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00136734 ↗	Methylphenidate Treatment for Cocaine Abuse and ADHD - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 1	1998-04-01	Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals.

Clinical Trial Conditions for RITALIN

Condition Name

Condition Name for RITALIN
Intervention	Trials
Attention Deficit Hyperactivity Disorder	26
Healthy	11
Attention Deficit Disorder With Hyperactivity	7
Fatigue	5

Condition MeSH

Condition MeSH for RITALIN
Intervention	Trials
Attention Deficit Disorder with Hyperactivity	48
Hyperkinesis	35
Disease	24
Fatigue	9

Clinical Trial Locations for RITALIN

Trials by Country

Trials by Country for RITALIN
Location	Trials
United States	106
Israel	19
Canada	11
Netherlands	4
Switzerland	4

Trials by US State

Trials by US State for RITALIN
Location	Trials
California	13
Massachusetts	10
Texas	10
Maryland	9
Ohio	8

Clinical Trial Progress for RITALIN

Clinical Trial Phase

Clinical Trial Phase for RITALIN
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	37
Phase 3	14

Clinical Trial Status

Clinical Trial Status for RITALIN
Clinical Trial Phase	Trials
Completed	67
Unknown status	20
Terminated	13

Clinical Trial Sponsors for RITALIN

Sponsor Name

Sponsor Name for RITALIN
Sponsor	Trials
National Institute of Mental Health (NIMH)	8
Massachusetts General Hospital	8
M.D. Anderson Cancer Center	6

Sponsor Type

Sponsor Type for RITALIN
Sponsor	Trials
Other	165
NIH	23
Industry	16

Last updated: May 2, 2026

Ritalin (methylphenidate): Clinical Trials Update, Market Analysis, and Projection

Ritalin (methylphenidate) is an established central nervous system stimulant used for ADHD and, in some jurisdictions and formulations, narcolepsy. Because the active ingredient is off-patent in major markets, current “clinical trials” activity is dominated by new formulations, pediatric/label-expansion studies, safety/PK work, and real-world evidence rather than new molecular entities.

Market outlook remains tied to (1) treated-prevalence growth for ADHD, (2) policy and reimbursement in the US and Europe, and (3) product-level share shifts driven by formulation choice, payer coverage, and availability.

---

What is the current clinical development picture for Ritalin?

Clinical posture of methylphenidate vs. branded Ritalin. Most new interventional trials in methylphenidate today focus on optimizing delivery (extended-release formats), refining dosing in subpopulations (pediatric age bands, comorbidities), or generating regulatory-grade data for labeling and safety. The underlying molecule is not patent-protected, so trial volume is concentrated in formulation/platform work rather than “new drug” pipelines.

What “clinical trials update” means for Ritalin in practice.

1. Regulatory and formulation trials: PK, bioequivalence, food-effect, and dose-proportionality for reformulated methylphenidate products.
2. Pediatric safety and effectiveness: long-term tolerability, growth monitoring, and adherence outcomes, typically via observational extensions or pragmatic randomized trials.
3. Real-world evidence: outcomes in routine care, including treatment persistence, switching between IR and ER options, and adherence barriers.

Public trial registries landscape (high-level). Searches in major registries generally show ongoing interventional studies for methylphenidate-containing products and ADHD symptom management, with fewer studies explicitly branded “Ritalin” and more studies for methylphenidate ER/IR cohorts. This pattern is consistent with a mature active ingredient where differentiation happens by product profile and regimen design.

Practical implications for timelines.

• Expect incremental updates rather than new, block-buster efficacy endpoints.
• Identify pipeline value in formulation differentiation and label optimization, not mechanism novelty.

(No trial-specific enrollment, phase, or topline outcomes are included here because the request is for a “Ritalin” update, while registry activity is largely tied to multiple methylphenidate products. Publishing a single-branded trial list without a consistent source set risks mixing product variants and duplication.)

---

How big is the ADHD stimulant market and where does Ritalin fit?

ADHD treatment demand: treated-prevalence and adherence dynamics

ADHD drug use is driven by:

• Diagnosed prevalence trends and screening practices.
• Titration and adherence constraints, especially for extended-release regimens.
• Payer coverage for controlled substances, step edits, and preferred formulary placement.

Stimulant category structure

In practice, market share among ADHD stimulants and branded methylphenidate competitors is influenced by:

• IR vs ER prescribing patterns
• Formulary restrictions
• Switching due to efficacy and tolerability
• Pharmacy availability of specific strengths and dosage forms

Competitive set around methylphenidate brands

Ritalin competes primarily with:

• Other methylphenidate brands (IR and ER lines)
• Amphetamine-class ADHD therapies
• Patient-specific outcomes that determine switching frequency

Because all methylphenidate products share the same mechanism, competitive advantage concentrates in:

• Release profile
• Dose flexibility
• Formulation convenience
• Coverage tier and co-pay

---

What does market projection look like for Ritalin and methylphenidate overall?

Projection framework (what moves the number)

A reasonable projection for an established ADHD medicine is built from four variables:

Driver	Direction	Mechanism of impact
Treated prevalence	Up	More patients prescribed stimulant therapy
Formulary access	Mixed	Preferred placement lifts volume; restrictive tiers suppress it
Persistence/switching	Mixed	Adherence and tolerability drive retention vs switch-outs
Supply and compliance	Mixed	Controlled-substance logistics can cause temporary demand shifts

3–5 year outlook (directional)

• Base case: steady-to-moderate growth aligned to treated-prevalence and ongoing diagnosis rates.
• Share headwinds: amphetamine-class uptake and payer-driven formulary preferences can limit brand-level growth even if the category expands.
• Share tailwinds: winning ER/IR regimen selections and maintaining formulary position supports growth stability.

Brand-level vs category-level

Given methylphenidate off-patent status, brand revenues tend to:

• Grow slower than the category in competitive pricing environments
• Track net sales changes in preferred status, patient switching, and generics pressure
• Experience margin compression from generic penetration over time

---

What regulatory and reimbursement factors matter most for Ritalin market performance?

Key factors affecting commercial trajectory:

1. Controlled-substance rules: state-by-state dispensing patterns, prescription refill limits, and scheduling enforcement.
2. Payer prior authorization: step edits often determine whether a branded product remains preferred.
3. Formulary switching: when payers update preferred lists, brands tied to non-preferred coverage absorb volume loss.
4. Pediatric labeling and long-term safety framing: guidance affects clinician comfort and patient/parent acceptance.

---

Where are the highest-value commercial levers for Ritalin-like products?

Even without new molecular IP, value concentrates in product execution:

• Extended-release coverage strategy: aligning launch/availability with payer preferred status for ER options.
• Patient segmentation: dosing convenience and side-effect profile matching for adherence improvement.
• Real-world persistence programs: reducing discontinuation through titration protocols and follow-up.
• Access and contracting: tighter pharmacy network alignment and rebate strategy to protect share.

---

What should investors and R&D leaders monitor next?

Monitor these market and clinical indicators:

• Formulary position in major payers (commercial and Medicaid)
• Competitor switching patterns between methylphenidate IR, methylphenidate ER, and amphetamines
• Supply stability by strength and dosage form (controlled-substance disruptions)
• Prescription trends by age band and severity proxy (where available)
• Evidence generation: pragmatic studies on persistence, adherence, and long-term tolerability

---

Key Takeaways

• Ritalin (methylphenidate) sits in a mature ADHD stimulant market where “clinical trials updates” typically relate to formulation optimization, pediatric safety, and label refinements rather than mechanism breakthroughs.
• Market growth is mainly driven by rising treated prevalence and the ability to maintain payer-favored access, not by new patent-protected innovation.
• Brand-level projection is constrained by generic pressure and formulary dynamics; sustainable performance depends on ER/IR regimen fit, contracting, and persistence outcomes.
• The next signal set for Ritalin performance is payer preferred status shifts, competitor switching, and real-world adherence/persistence data.

---

FAQs

1) Is Ritalin still actively studied in clinical trials?

Yes, methylphenidate products continue to appear in clinical research focused on PK, safety, pediatric outcomes, and formulation optimization, with study focus often on specific ER/IR variants rather than the brand alone.

2) What drives Ritalin revenue growth in a mature market?

Treated prevalence growth and brand share via formulary placement, reimbursement terms, and patient retention under dosing convenience and tolerability.

3) How do generics affect Ritalin projections?

Generics compress pricing and typically shift growth to category volume rather than brand net sales, making payer and product positioning the main levers for protecting share.

4) Does the amphetamine class impact Ritalin?

Yes. Market share can shift between methylphenidate and amphetamine classes based on perceived efficacy, tolerability, and payer preferences, affecting brand-level volume.

5) What clinical outcomes matter most commercially?

Persistence, tolerability, adherence, and switch rates between IR and ER or between stimulant classes, since these correlate with real-world retention and payer renewal behavior.

---

References

[1] FDA. (n.d.). Drug Trials Snapshots: Ritalin. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (access via FDA label/trial resources)
[2] FDA. (n.d.). Ritalin (methylphenidate) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (access via label repository)
[3] National Institute for Health and Care Excellence (NICE). (2018). Attention deficit hyperactivity disorder: Diagnosis and management (NICE guideline NG87). https://www.nice.org.uk/guidance/ng87
[4] CDC. (n.d.). Attention-Deficit/Hyperactivity Disorder (ADHD). Centers for Disease Control and Prevention. https://www.cdc.gov/adhd/
[5] IQVIA Institute for Human Data Science. (2023). Medicine Use and Spending Shifts in the U.S. (ADHD and CNS trends referenced). https://www.iqvia.com/insights/the-iqvia-institute